Assessment of the Role of Orexin A and Some Clinical Parameters in Children with Autism Spectrum Disorder
DOI:
https://doi.org/10.21070/anamnetic.v3i1.1611Keywords:
Autism spectrum disorders, orexin A, 5- 5-hydroxytryptamine, glutamate, BMIAbstract
Objective: Autism spectrum disorder [ASD] is characterized by impairments in emotional, social, and cognitive areas and is considered a neurodevelopmental disorder. These children often exhibit stereotypical and repetitive manners that may be inconsistent with their inner physiological cadence, leading to disturbances in the Wake-up and sleep cycle. This study aimed to investigate the serum Orexin A, 5-HT, glutamate, and oxidative stress status and compare the values with those of healthy controls. Methods: This study included 40 participants, 20 patients, and 20 controls. The samples of children with ASD were obtained from the AL-Shatra unit of Autism Care//Thi Qar. Children taking medication and those with neurological diseases were excluded from the study. Serum orexin A, 5-HT, glutamate, NO, and albumen levels were assessed in all participants. Results: The means of serum orexin A, 5-HT, glutamate, and NO levels of patients with ASD were significantly higher than those of the control group (p <0.05). However, serum GSH and albumen levels were lower among the cases than the control group (p < 0.05). Conclusion: orexin A, 5-HT, and glutamate measurements taken together may even be utilized as markers for the development of sleep and eating disorders and insomnia. The rising levels of orexin A in uncontrolled autism spectrum disorder may be a cause of rising BMI. This assessment may be beneficial in developing an appropriate treatment plan for these children. This assessment may be instrumental in developing an appropriate treatment plan for these children and may form the basis for developing and directing targeted treatment in the future.
References
1- Kosillo, P.; Bateup, H.S. Dopaminergic Dysregulation in Syndromic Autism Spectrum Disorders: Insights from Genetic Mouse Models. Front. Neural Circuits 2021, 15, 700968.
2- Abg AbdWahab, D.Y.; Gau, C.H.; Zakaria, R.; Muthu Karuppan, M.K.; A-rahbi, B.S.; Abdullah, Z.; Alrafiah, A.; Abdullah, J.M.; Muthuraju, S. Review on Cross Talk between Neurotransmitters and Neuroinflammation in Striatum and Cerebellum in the Mediation of Motor Behaviour. Biomed Res. Int. 2019, 2019, 1767203.
3- Montanari, M.; Martella, G.; Bonsi, P.; Meringolo, M. Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission. Int. J. Mol. Sci. 2022, 23, 3861.
4- Tau, G.Z.; Peterson, B.S. Normal Development of Brain Circuits. Neuropsychopharmacology 2009, 35, 147–168.
5- Yin, W.; Chen, M.-H.; Hung, S.-C.; Baluyot, K.R.; Li, T.; Lin, W. Brain Functional Development Separates into Three Distinct Time Periods in the First Two Years of Life. NeuroImage 2019, 189, 715–726.
6- Johnson KP, Zarrinnegar P.Autism spectrum disorder and sleep. Child
Adolesc Psychiatr Clin N Am 2021;30(1):195–208
7- Petti T, Gupta M, Fradkin Y, Gupta N. Management of sleep disorders in autism spectrum disorder with co-occurring attentiondeficit hyperactivity disorder: update for clinicians. BJPsych Open 2023;10(1).
8- Arocha Rodulfo, G. Aure Fariñez, F. Carrera Sleep and cardiometabolic risk. Narrative revision Clín Invest Arterioscler, 36 (1) (2024 Jan-Feb), pp. 38-49.
9- M.P. St-Onge, M.A. Grandner, D. Brown, M.B. Conroy, G. Jean-Louis, M. Coons, D.L. Bhatt, American Heart Association Obesity Behavior change, diabetes, and nutrition committees of the council on lifestyle and cardiometabolic health; council on cardiovascular disease in the young; council on clinical cardiology; and stroke council. Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American heart association
Circulation, 134 (18) (2016 Nov 1), pp. e367-e386,
10- Arya, A.; Sindhwani, G. Autism: An early-onset neurodevelopmental disorder. Int. J. Pharm. Sci. Res. 2016, 7, 3567.
11- Rosa Marotta , Maria C Risoleo , Giovanni Messina , Lucia Parisi et al , The Neurochemistry of Autism; Brain Sci. 2020, 10, 163.
12- Zhao H, Chen S, Hu K, Zhang Z, Yan X, Gao H, et al. 5-HTP decreases goat mammary epithelial cells apoptosis through MAPK/ERK/Bcl-3 pathway. Gene 2021;769:145240.
13- Bilc MI, Iacob A, Szekely-Copindean RD, Kiss B, Stefan MG, Muresan RC, et al. Serotonin and emotion regulation: the impact of tryptophan depletion on emotional experience, neural and autonomic activity. Cogn Affect Behav Neurosci 2023;23(5):1414–27.
14- Brosnan, J.T.; Brosnan, M.E. Glutamate: A Truly Functional Amino Acid. Amino Acids 2013, 45, 413–418.
15- Popoli, M.; Yan, Z.; McEwen, B.S.; Sanacora, G. The Stressed Synapse: The Impact of Stress and Glucocorticoids on Glutamate Transmission. Nat. Rev. Neurosci. 2012, 13, 22–37.
16- Sanacora, G.; Treccani, G.; Popoli, M. Towards a Glutamate Hypothesis of Depression. Neuropharmacology 2012, 62, 63–77.
17- Xie, R.-G.; Xu, G.-Y.; Wu, S.-X.; Luo, C. Presynaptic Glutamate Receptors in Nociception. Pharmacol. Ther. 2023, 251, 108539.
18- Cox, M.F.; Hascup, E.R.; Bartke, A.; Hascup, K.N. Friend or Foe? Defining the Role of Glutamate in Aging and Alzheimer’s Disease. Front. Aging 2022, 3, 929474.
19- Nicosia, N.; Giovenzana, M.; Misztak, P.; Mingardi, J.; Musazzi, L. Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders. Int. J. Mol. Sci. 2024, 25, 6521.
20- Mieda, M.; Tsujino, N.; Sakurai, T. Differential Roles of Orexin Receptors in the Regulation of Sleep/Wakefulness. Front. Endocrinol. 2013, 4, 57.
21- Ouaidat, S.; Amaral, I.M.; Monteiro, D.G.; Harati, H.; Hofer, A.; El Rawas, R. Orexins/Hypocretins: Gatekeepers of Social Interaction and Motivation. Int. J. Mol. Sci. 2024, 25, 2609.
22- Li, H.; Lu, J.; Li, S.; Huang, B.; Shi, G.; Mou, T.; Xu, Y. Increased Hypocretin (Orexin) Plasma Level in Depression, Bipolar Disorder Patients. Front. Psychiatry 2021, 31, 676336.
23- Li, H.; Lu, J.; Li, S.; Huang, B.; Shi, G.; Mou, T.; Xu, Y. Increased Hypocretin (Orexin) Plasma Level in Depression, Bipolar Disorder Patients. Front. Psychiatry 2021, 31, 676336.
24- Dervisevic A, Babic N, Huskic J, et al. Concentration of nitric oxide in saliva of patients with rheumatoid arthritis. Int J Collab Res Intern Med Public Health. 2012;4(7):1442–51.
25- Ellman, G. L. Tissue sulfhydryl groups. Archeves Biochemistry and biophysics, 1959 82, 70-77.
26- Kodak T, Bergmann S. Autism spectrum disorder: characteristics, associated behaviors, and early intervention. Pediatr Clin North Am 2020;67(3):525–35.
27- Genovese A, Butler MG. Clinical assessment, genetics, and treatment approaches in autism spectrum disorder (ASD). Int J Mol Sci 2020;21(13):4726.
28- Research progress on melatonin, 5-HT, and orexin in sleep disorders of children with autism spectrum disorder. Biomol Biomed . 2025;25(3):525–533.
29- Muehlan C, Roch C, Vaillant C, Dingemanse J. The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res
2023;32(6):e13902.
30- Thomas RP, Milan S, Naigles L, Robins DL, Barton ML, Adamson LB, et al. Symptoms of autism spectrum disorder and developmental delay in children with low mental age. Clin Neuropsychol 2022;36(5):1028– 48.
31- Kohyama J. Possible neuronal mechanisms of sleep disturbances in patients with autism spectrum disorders and attention-deficit/hyperactivity disorder. Med Hypotheses. 2016;97:131–133.
32- National Institute of Mental Health. Definitions of the RDoC Domains and Constructs. Available from: https://www.nimh.nih.gov/research/ research-funded-by-nimh/rdoc. Accessed September 17, 2022.9.
33- Stahl S, Morrissette D. Stahl’s Illustrated Sleep and Wake Disorders. Cambridge University Press; 2016.37.
34- Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): the ultimate translational neuropeptides. J Intern Med. 2022;291:533–556.
35- Sakurai T, Saito YC, Yanagisawa M. Interaction between orexin neurons and monoaminergic systems. Front Neurol Neurosci. 2021;45:11–21.
36- Xiao, J. , Song, M. , Li, F. , Liu, X. , Anwar, A. , & Zhao, H. Effects of GABA microinjection into dorsal raphe nucleus on behavior and activity of lateral habenular neurons in mice. Experimental Neurology, 2017. 298, 23–30.
37- Choi, W. , Moon, J. H. , & Kim, H.. Serotonergic regulation of energy metabolism in peripheral tissues. The Journal of Endocrinology, 2020,245(1), R1–R10. 10.1530/JOE-19-0546.
38- Kapalka, G.M. Substances Involved in Neurotransmission. In Practical Resources for the Mental Health Professional, Nutritional and Herbal Therapies for Children and Adolescents; Kapalka, G.M., Ed.; Academic Press: Cambridge, MA, USA; Elsevier: San Diego, CA, USA, 2010; pp. 71–99.
39- Shimmura, C.; Suzuki, K.; Iwata, Y.; Tsuchiya, K.J.; Ohno, K.; Matsuzaki, H.; Iwata, K.; Kameno, Y.; Takahashi, T.;Wakuda, T.; et al. Enzymes in the Glutamate-Glutamine Cycle in the Anterior Cingulate Cortex in Postmortem Brain of Subjects with Autism.
Mol. Autism 2013, 4, 6.
40- Ayano, G. Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and Mental Disorders: Review of Literatures. J. Nerv. Ment. Dis. 2016, 2, 2.
41- Fernández, M.; Mollinedo-Gajate, I.; Peñagarikano, O. Neural Circuits for Social Cognition: Implications for Autism. Neuroscience 2018, 370, 148–162.
42- Montanari, M.; Martella, G.; Bonsi, P.; Meringolo, M. Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission. Int. J. Mol. Sci. 2022, 23, 3861.
43- El-Ansary, A.; Al-Ayadhi, L. GABAergic/Glutamatergic Imbalance Relative to Excessive Neuroinflammation in Autism Spectrum Disorders. J. Neuroinflamm. 2014, 11, 189.
44- Velasco, M.; Quintero, J.R.; Castillo, M.C.; Rojas, M.; Bautista, J.; Martinez, M.S.; Salazar, J.; Mendoza, R.; Bermudez, V. Excitotoxicity: An Organized Crime at The Cellular Level. J. Neurol. Neurosci. 2017, 8, 193.
45- Verma, M.; Lizama, B.N.; Chu, C.T. Excitotoxicity, Calcium and Mitochondria: A Triad in Synaptic Neurodegeneration. Transl. Neurodegener. 2022, 11, 3.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sarah Sayer
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
